非小细胞肺癌患者T细胞检查点阻断治疗期间抗体介导的甲状腺功能障碍
在纪念斯隆凯特琳癌症中心接受帕博利珠单抗治疗的51例晚期非小细胞肺癌患者中,48例基线甲状腺功能正常者中有10例(21%,95%CI 10%至35%)出现需要甲状腺替代治疗的甲状腺功能障碍。甲状腺功能障碍发生早(中位42天),多数(10例中6例)先出现短暂性甲状腺功能亢进,且与抗甲状腺抗体密切相关(80% vs 8%,P<0.0001)。出现甲状腺功能障碍者总生存显著更长(HR 0.29,95%CI 0.09-0.94,P=0.04)。
要点
- 帕博利珠单抗治疗中21%基线甲状腺功能正常患者出现需替代治疗的甲状腺功能障碍。
- 甲状腺功能障碍发生早(中位42天),多先有短暂性甲状腺功能亢进,与抗甲状腺抗体密切相关。
- 出现甲状腺功能障碍者总生存显著更长(HR 0.29,95%CI 0.09-0.94,P=0.04)。
核心结论
- 帕博利珠单抗治疗非小细胞肺癌时甲状腺功能障碍常见,特征为早发、常先有短暂性甲状腺功能亢进、与抗甲状腺抗体密切相关,并可能与结局改善相关。
研究设计与样本
- 研究纳入在纪念斯隆凯特琳癌症中心作为KEYNOTE-001(NCT01295827)一部分接受帕博利珠单抗治疗的晚期非小细胞肺癌患者51例。
- 每次研究访视时前瞻性评估甲状腺功能试验和抗甲状腺抗体,从首次治疗前开始。
- 评估甲状腺功能障碍发生频率、与抗甲状腺抗体的关联、临床病程及其与无进展生存和总生存的关系。
主要发现
- 51例患者中,基线时3例甲状腺功能减退、48例甲状腺功能正常。
- 48例基线甲状腺功能正常者中10例(21%,95%CI 10%至35%)出现需要甲状腺替代治疗的甲状腺功能障碍。
- 出现甲状腺功能障碍的10例中8例存在抗甲状腺抗体,未出现者38例中3例存在(80% vs 8%,P<0.0001)。
- 甲状腺功能障碍发生早(中位42天),多数(10例中6例)在甲状腺功能减退前出现短暂性甲状腺功能亢进,无持续性甲状腺功能亢进。
- 甲状腺功能亢进和甲状腺功能减退大多无症状;出现甲状腺功能障碍者总生存显著更长(HR 0.29,95%CI 0.09-0.94,P=0.04)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Programmed cell death protein-1 (PD-1) blockade therapies have demonstrated durable responses and prolonged survival in a variety of malignancies. Treatment is generally well tolerated although immune-related adverse events (irAEs) can occur. Autoimmune thyroid dysfunction is among the most common irAE, but an assessment of the clinical, mechanistic, and immunologic features has not been previously described. PATIENT AND METHODS: Patients with advanced non-small-cell lung cancer (NSCLC) treated with pembrolizumab at Memorial Sloan Kettering Cancer Center (n = 51) as part of KEYNOTE-001 (NCT01295827) were included. Thyroid function test and anti-thyroid antibodies were assessed prospectively at each study visit, beginning before the first treatment. Frequency of development of thyroid dysfunction, association with anti-thyroid antibodies, clinical course, and relationship with progression-free survival and overall survival to treatment with pembrolizumab was evaluated. RESULTS: Of 51 patients treated, 3 were hypothyroid and 48 were not at baseline. Ten of 48 [21%, 95% confidence interval (CI) 10% to 35%] patients developed thyroid dysfunction requiring thyroid replacement. Anti-thyroid antibodies were present in 8 of 10 patients who developed thyroid dysfunction, compared with 3 of 38 who did not (80% versus 8%, P < 0.0001). Thyroid dysfunction occurred early (median, 42 days) in the pembrolizumab course, and a majority (6 of 10 patients) experienced brief, transient hyperthyroidism preceding the onset of hypothyroidism; no persistent hyperthyroidism occurred. Both hyperthyroidism and hypothyroidism were largely asymptomatic. Overall survival with pembrolizumab was significantly longer in subjects who developed thyroid dysfunction (hazard ratio, 0.29; 95% CI 0.09-0.94; P = 0.04). CONCLUSIONS: Thyroid dysfunction during pembrolizumab treatment of NSCLC is common and is characterized by early-onset, frequently preceded by transient hyperthyroidism, closely associated with anti-thyroid antibodies, and may be associated with improved outcomes. The presence of antibody-mediated toxicity in T-cell-directed therapy suggests an under-recognized impact of PD-1 biology in modulating humoral immunity.
引用
- Osorio JC, Ni A, Chaft JE, et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol. 2017. PMID: 27998967. doi:10.1093/annonc/mdw640
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。